Standard

Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer. / Koole, S. N.; Kieffer, J. M.; K.Sikorska; Schagen van Leeuwen, J. H.; Schreuder, H. W. R.; Hermans, R. H.; de Hingh, I. H.; van der Velden, J.; Arts, H. J.; van Ham, M. A. P. C.; Aalbers, A. G.; Verwaal, V. J.; van de Vijver, K. K.; Sonke, G. S.; van Driel, W. J.; Aaronson, N. K.

In: European journal of surgical oncology, 13.05.2019.

Research output: Contribution to journalReview articleAcademicpeer-review

Harvard

Koole, SN, Kieffer, JM, K.Sikorska, Schagen van Leeuwen, JH, Schreuder, HWR, Hermans, RH, de Hingh, IH, van der Velden, J, Arts, HJ, van Ham, MAPC, Aalbers, AG, Verwaal, VJ, van de Vijver, KK, Sonke, GS, van Driel, WJ & Aaronson, NK 2019, 'Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer', European journal of surgical oncology. https://doi.org/10.1016/j.ejso.2019.05.006

APA

Koole, S. N., Kieffer, J. M., K.Sikorska, Schagen van Leeuwen, J. H., Schreuder, H. W. R., Hermans, R. H., ... Aaronson, N. K. (2019). Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer. European journal of surgical oncology. https://doi.org/10.1016/j.ejso.2019.05.006

Vancouver

Koole SN, Kieffer JM, K.Sikorska, Schagen van Leeuwen JH, Schreuder HWR, Hermans RH et al. Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer. European journal of surgical oncology. 2019 May 13. https://doi.org/10.1016/j.ejso.2019.05.006

Author

Koole, S. N. ; Kieffer, J. M. ; K.Sikorska ; Schagen van Leeuwen, J. H. ; Schreuder, H. W. R. ; Hermans, R. H. ; de Hingh, I. H. ; van der Velden, J. ; Arts, H. J. ; van Ham, M. A. P. C. ; Aalbers, A. G. ; Verwaal, V. J. ; van de Vijver, K. K. ; Sonke, G. S. ; van Driel, W. J. ; Aaronson, N. K. / Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer. In: European journal of surgical oncology. 2019.

BibTeX

@article{9535dba6d36f439d9e65c78044e582f4,
title = "Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer",
abstract = "Introduction: The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery (CRS) improves recurrence-free (RFS) and overall survival (OS) in patients with FIGO stage III ovarian cancer. We evaluated the effect of HIPEC on patient's health-related quality of life (HRQoL) in the OVHIPEC trial. Materials and methods: OVHIPEC was a multicentre, open-label, randomized phase III trial for patients with stage III ovarian cancer. Patients were randomly assigned (1:1) to receive interval CRS with or without HIPEC with cisplatin. HRQoL was assessed using the EORTC QLQ-C30, and the ovarian (QLQ-OV28) and colorectal cancer (QLQ-CR38) modules. HRQoL questionnaires were administered at baseline, after surgery, after end of treatment, and every three months thereafter. HRQoL was a secondary endpoint, with the prespecified focus on the QLQ-C30 summary score and symptom scores on fatigue, neuropathy and gastro-intestinal symptoms. HRQoL was analysed using linear and non-linear mixed effect models. Results: In total, 245 patients were randomized. One-hundred-ninety-seven patients (80{\%}) completed at least one questionnaire. No significant difference over time in the QLQ-C30 summary scores was observed between the study arms (p-values for linear and non-linear growth: p > 0.133). The pattern over time for fatigue, neuropathy and gastro-intestinal symptoms did not significantly differ between treatment arms. Conclusion: The addition of HIPEC to interval CRS does not negatively impact HRQoL in patients with stage III ovarian cancer who are treated with interval CRS due to the extent of disease. These HRQoL results, together with the improvement in RFS and OS, support the viability of HIPEC as an important treatment option in this patient population. ClinicalTrials.gov number: NCT00426257. EudraCT number: 2006-003466-34.",
author = "Koole, {S. N.} and Kieffer, {J. M.} and K.Sikorska and {Schagen van Leeuwen}, {J. H.} and Schreuder, {H. W. R.} and Hermans, {R. H.} and {de Hingh}, {I. H.} and {van der Velden}, J. and Arts, {H. J.} and {van Ham}, {M. A. P. C.} and Aalbers, {A. G.} and Verwaal, {V. J.} and {van de Vijver}, {K. K.} and Sonke, {G. S.} and {van Driel}, {W. J.} and Aaronson, {N. K.}",
note = "Copyright {\circledC} 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.",
year = "2019",
month = "5",
day = "13",
doi = "10.1016/j.ejso.2019.05.006",
language = "English",
journal = "European journal of surgical oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",

}

RIS

TY - JOUR

T1 - Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer

AU - Koole, S. N.

AU - Kieffer, J. M.

AU - K.Sikorska, null

AU - Schagen van Leeuwen, J. H.

AU - Schreuder, H. W. R.

AU - Hermans, R. H.

AU - de Hingh, I. H.

AU - van der Velden, J.

AU - Arts, H. J.

AU - van Ham, M. A. P. C.

AU - Aalbers, A. G.

AU - Verwaal, V. J.

AU - van de Vijver, K. K.

AU - Sonke, G. S.

AU - van Driel, W. J.

AU - Aaronson, N. K.

N1 - Copyright © 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

PY - 2019/5/13

Y1 - 2019/5/13

N2 - Introduction: The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery (CRS) improves recurrence-free (RFS) and overall survival (OS) in patients with FIGO stage III ovarian cancer. We evaluated the effect of HIPEC on patient's health-related quality of life (HRQoL) in the OVHIPEC trial. Materials and methods: OVHIPEC was a multicentre, open-label, randomized phase III trial for patients with stage III ovarian cancer. Patients were randomly assigned (1:1) to receive interval CRS with or without HIPEC with cisplatin. HRQoL was assessed using the EORTC QLQ-C30, and the ovarian (QLQ-OV28) and colorectal cancer (QLQ-CR38) modules. HRQoL questionnaires were administered at baseline, after surgery, after end of treatment, and every three months thereafter. HRQoL was a secondary endpoint, with the prespecified focus on the QLQ-C30 summary score and symptom scores on fatigue, neuropathy and gastro-intestinal symptoms. HRQoL was analysed using linear and non-linear mixed effect models. Results: In total, 245 patients were randomized. One-hundred-ninety-seven patients (80%) completed at least one questionnaire. No significant difference over time in the QLQ-C30 summary scores was observed between the study arms (p-values for linear and non-linear growth: p > 0.133). The pattern over time for fatigue, neuropathy and gastro-intestinal symptoms did not significantly differ between treatment arms. Conclusion: The addition of HIPEC to interval CRS does not negatively impact HRQoL in patients with stage III ovarian cancer who are treated with interval CRS due to the extent of disease. These HRQoL results, together with the improvement in RFS and OS, support the viability of HIPEC as an important treatment option in this patient population. ClinicalTrials.gov number: NCT00426257. EudraCT number: 2006-003466-34.

AB - Introduction: The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery (CRS) improves recurrence-free (RFS) and overall survival (OS) in patients with FIGO stage III ovarian cancer. We evaluated the effect of HIPEC on patient's health-related quality of life (HRQoL) in the OVHIPEC trial. Materials and methods: OVHIPEC was a multicentre, open-label, randomized phase III trial for patients with stage III ovarian cancer. Patients were randomly assigned (1:1) to receive interval CRS with or without HIPEC with cisplatin. HRQoL was assessed using the EORTC QLQ-C30, and the ovarian (QLQ-OV28) and colorectal cancer (QLQ-CR38) modules. HRQoL questionnaires were administered at baseline, after surgery, after end of treatment, and every three months thereafter. HRQoL was a secondary endpoint, with the prespecified focus on the QLQ-C30 summary score and symptom scores on fatigue, neuropathy and gastro-intestinal symptoms. HRQoL was analysed using linear and non-linear mixed effect models. Results: In total, 245 patients were randomized. One-hundred-ninety-seven patients (80%) completed at least one questionnaire. No significant difference over time in the QLQ-C30 summary scores was observed between the study arms (p-values for linear and non-linear growth: p > 0.133). The pattern over time for fatigue, neuropathy and gastro-intestinal symptoms did not significantly differ between treatment arms. Conclusion: The addition of HIPEC to interval CRS does not negatively impact HRQoL in patients with stage III ovarian cancer who are treated with interval CRS due to the extent of disease. These HRQoL results, together with the improvement in RFS and OS, support the viability of HIPEC as an important treatment option in this patient population. ClinicalTrials.gov number: NCT00426257. EudraCT number: 2006-003466-34.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85065865300&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/31128948

U2 - 10.1016/j.ejso.2019.05.006

DO - 10.1016/j.ejso.2019.05.006

M3 - Review article

C2 - 31128948

JO - European journal of surgical oncology

JF - European journal of surgical oncology

SN - 0748-7983

ER -

ID: 6497228